Online pharmacy DocMorris has faced enforcement measures amounting to €110,000 in the Netherlands, initiated by the Apothekerkammer Nordrhein. According to the chamber, DocMorris violated binding German court judgments regarding advertising practices and discounts following legal proceedings lost in Stuttgart years ago. Although plaintiffs previously applied for fines in Germany, those efforts stalled, prompting the German pharmacists to pursue enforcement through a Dutch court where they succeeded in the first instance.
The Apothekerkammer Nordrhein stated that the ruling reinforces the principle that legally binding court decisions cannot be undermined by a company relocating its headquarters to another European Union member state, and that those who disregard judgments must pay the resulting penalties. DocMorris confirmed that the matter involves the enforcement of administrative fines from an isolated 2020 legal dispute, adding that the case has no strategic relevance, operational impact, or effect on financial stability. The company stated it has nevertheless decided to appeal the matter to achieve a definitive clarification of the legal situation.
DocMorris operates primarily in the German market while maintaining its headquarters just across the Dutch border near Aachen, benefiting from the EU single market's cross-border trade provisions. Because it is structured as a capital company selling pharmaceuticals, DocMorris cannot be based in Germany, where physical pharmacy operations are restricted to pharmacists. Traditional local pharmacists, who bear the costs of brick-and-mortar locations, have contested the online competitor over differing competitive conditions and potential impacts on local supply networks, while DocMorris maintains that providers based in other EU states must not face disadvantage contrary to European law.
